Inactive Instrument

Findit, Inc. Stock Other OTC

Equities

FDIT

US31772N1000

Medical Equipment, Supplies & Distribution

Sales 2022 2.44M Sales 2023 22.24K Capitalization 32.52M
Net income 2022 -2M Net income 2023 - EV / Sales 2022 * -
Net cash position 2022 * - Net cash position 2023 * - EV / Sales 2023 * -
P/E ratio 2022 *
-
P/E ratio 2023 *
-
Employees -
Yield 2022 *
-
Yield 2023 *
-
Free-Float 4.61%
More Fundamentals * Assessed data
Dynamic Chart
BioRegenx, Inc. completed the acquisition of Findit, Inc. from WooEB, Inc., Hva Family Trust and others in a reverse merger transaction. CI
Findit, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Findit, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Findit, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Findit, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Findit, Inc. Auditor Raises 'Going Concern' Doubt CI
BioRegenx, Inc. entered into a Definitive Agreement to acquire Findit, Inc. in a reverse merger transaction. CI
Findit, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Findit, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Findit, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Findit, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Findit, Inc. Auditor Raises 'Going Concern' Doubt CI
Findit, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Findit, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Virtual Class Services, Inc. announced that it has received $0.01 million in funding from Findit, Inc. CI
More news
BioRegenx, Inc., formerly Findit, Inc., operates as a holding company. The Company specializes in acquiring intellectual property (IP) and companies engaged in regenerative biotherapeutics and anti-aging research. Its primary focus involves acquiring and developing non-invasive medical and wellness devices capable of efficiently recording, storing, and analyzing datasets. The Company’s patented technologies and solutions include GlycoCheck, a high-definition video imaging that analyzes five parameters of microvascular health non-invasively with an under the tongue test using patented technology; Endocalyx Pro, an all-natural, plant-based patented nutraceutical shown to restore, regenerate, and protect microvascular health. Clinically tested in multiple double-blind placebo studies, and DocSun, an artificial intelligence using three advanced facial recognition technologies that analyzes 21 vital signs and health indicators without physical contact.
More about the company